Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
A
• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)
• attention-deficit-hyperactivity-disorder-adhd (5)
B
C
D
• d9-tetrahydrocannabinol-thc (4)
• d9-tetrahydrocannabinolic-acid-thca (1)
E
• endocannabinoid-system-ecs (45)
F
G
• gastrointestinal-disease (6)
H
I
K
L
M
N
• national-institute-on-drug-abuse-nida (1)
• neuro-protective-and-neuro-generative (7)
P
S
T
• traumatic-brain-injury-tbi (1)
• View All (505)A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers (2013)
The objective of this study was to evaluate the possible drug interactions of the oromucosal aerosol of THC and CBD Sativex�, nabiximols in combination with the cytochrome P450 (CYP450) inducer (rifampin) or inhibitors (ketoconazole or omeprazole). Based on our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes in the PK parameters of the THC / CBD spray, but potential effects should be considered when co-administered THC / CBD with compounds that share the CYP3A4 pathway like rifampicin or ketoconazole. View study
Interactions between cannabidiol and commonly used antiepileptic drugs (2017)
In this study, the possible interactions between cannabidiol (CBD) and common antiepileptic drugs (AED) were identified. View study